Cargando…
SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?
Autores principales: | Kuster, Gabriela M, Pfister, Otmar, Burkard, Thilo, Zhou, Qian, Twerenbold, Raphael, Haaf, Philip, Widmer, Andreas F, Osswald, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184407/ https://www.ncbi.nlm.nih.gov/pubmed/32196087 http://dx.doi.org/10.1093/eurheartj/ehaa235 |
Ejemplares similares
-
Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients
por: Vischer, Annina S., et al.
Publicado: (2021) -
Effects of Vitamin D on the Renin–Angiotensin System and Acute Childhood Pneumonia
por: Zovi, Andrea, et al.
Publicado: (2022) -
The renin–angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications
por: Diamond, Betty
Publicado: (2020) -
Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations
por: Hanff, Thomas C, et al.
Publicado: (2020) -
Influence of renin‐angiotensin‐aldosterone system inhibitors on plasma levels of angiotensin‐converting enzyme 2
por: Zimmermann, Tobias, et al.
Publicado: (2021)